N4 Pharma (N4P) Competitors GBX 0.62 -0.01 (-1.28%) As of 10/3/2025 12:06 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsBuy This Stock N4P vs. PXS, MXC, RGT, CEL, CHLL, HELD, HLN, HIK, HCM, and INDVShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Provexis (PXS), Argent BioPharma (MXC), Argent BioPharma (RGT), Celadon Pharmaceuticals (CEL), Chill Brands Group (CHLL), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), and Indivior (INDV). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Its Competitors Provexis Argent BioPharma Argent BioPharma Celadon Pharmaceuticals Chill Brands Group Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior N4 Pharma (LON:N4P) and Provexis (LON:PXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership. Which has more risk and volatility, N4P or PXS? N4 Pharma has a beta of -0.37, suggesting that its share price is 137% less volatile than the S&P 500. Comparatively, Provexis has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Do institutionals and insiders have more ownership in N4P or PXS? 0.2% of N4 Pharma shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 22.0% of N4 Pharma shares are owned by company insiders. Comparatively, 11.8% of Provexis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is N4P or PXS more profitable? Provexis has a net margin of -73.10% compared to N4 Pharma's net margin of -18,399.86%. Provexis' return on equity of -68.68% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets N4 Pharma-18,399.86% -90.68% -56.00% Provexis -73.10%-68.68%-56.14% Which has preferable earnings & valuation, N4P or PXS? Provexis has higher revenue and earnings than N4 Pharma. Provexis is trading at a lower price-to-earnings ratio than N4 Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioN4 Pharma£7.07K726.74-£1.63M-£0.00-257.08Provexis£1.20M12.07-£619.15K-£0.00-2,058.33 Does the media favor N4P or PXS? In the previous week, Provexis had 1 more articles in the media than N4 Pharma. MarketBeat recorded 1 mentions for Provexis and 0 mentions for N4 Pharma. N4 Pharma's average media sentiment score of 0.00 beat Provexis' score of -0.71 indicating that N4 Pharma is being referred to more favorably in the media. Company Overall Sentiment N4 Pharma Neutral Provexis Negative SummaryProvexis beats N4 Pharma on 8 of the 13 factors compared between the two stocks. Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding N4P and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£5.20M£1.74B£6.12B£2.59BDividend Yield3.12%2.95%5.65%5.30%P/E Ratio-257.08116.3786.964,424.90Price / Sales726.741,568.89605.4199,677.99Price / Cash2.2510.3737.9027.90Price / Book1.3811.4912.558.04Net Income-£1.63M£20.70B£3.31B£5.89B7 Day Performance-10.58%4.45%4.28%4.35%1 Month Performance12.18%4.25%6.90%6.26%1 Year Performance12.18%9.68%70.54%143.90% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.62-1.3%N/A+2.8%£5.20M£7.07K-257.085Gap DownPXSProvexisN/AGBX 0.62flatN/A+2.9%£14.49M£1.20M-2,058.334High Trading VolumeMXCArgent BioPharmaN/AN/AN/AN/A£9.65M£1.32M-13.255Gap UpRGTArgent BioPharmaN/AN/AN/AN/A£8.31MN/A-0.65N/AGap DownHigh Trading VolumeCELCeladon PharmaceuticalsN/AGBX 13.40flatN/AN/A£8.22M£123.38K-1.682,780CHLLChill Brands GroupN/AGBX 1.58+1.7%N/AN/A£8.11M£305.70K-242.627Gap DownHELDHellenic DynamicsN/AGBX 0.01flatN/AN/A£14KN/A0.00N/AHLNHaleon2.2929 of 5 starsGBX 331.10+0.4%GBX 436.67+31.9%-14.4%£29.36B£11.02B1,982.6325,408HIKHikma Pharmaceuticals3.8296 of 5 starsGBX 1,845+0.7%GBX 2,627.50+42.4%-3.1%£4.06B£3.22B1,104.799,100HCMHUTCHMEDN/AGBX 242+2.5%N/A-21.9%£2.03B£602.20M456.601,760INDVIndivior2.0446 of 5 starsGBX 1,238+1.6%GBX 1,800+45.4%+57.8%£1.93B£1.40B-1,026.481,000News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Provexis Alternatives Argent BioPharma Alternatives Argent BioPharma Alternatives Celadon Pharmaceuticals Alternatives Chill Brands Group Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:N4P) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free N4P Stock Alerts